Get started
LIVZON PHARMACEUTILL

LIVZON PHARMACEUTI

36.40CNYD
+0.21+0.58%
At close at May 30, 08:49 GMT
CNY
No trades
See on Supercharts
Overview
Financials
News Discussions Technicals Forecast Seasonals

000513 fundamentals

Key facts

Market capitalization‪29.94 B‬CNY
Dividend yield (indicated)3.02%
Price to earnings Ratio (TTM)15.77
Basic EPS (TTM)2.30CNY
Founded1992
Employees (FY)‪9.07 K‬
CEO—
Websitelivzon.com.cn
About

Livzon Pharmaceutical Group, Inc. engages in the research and development, production, and distribution of pharmaceutical products. It offers drug preparation products, bulk medicines and intermediates, and diagnostic reagents and equipment. The company was founded on March 1, 1992, and is headquartered in Zhuhai, China.

Ownership
‪‪594.87 M‬‬
Free Float shares
‪‪336.46 M‬‬ (56.56%)
Closely held shares
‪‪258.40 M‬‬ (43.44%)
Free Float shares
‪‪336.46 M‬‬ (56.56%)
Closely held shares
‪‪258.40 M‬‬ (43.44%)
Capital structure
Market cap
‪‪29.94 B‬‬
Debt
‪‪4.81 B‬‬
Minority interest
‪‪1.21 B‬‬
Cash & equivalents
‪‪10.90 B‬‬
Enterprise value
‪‪25.06 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪29.94 B‬‬
Price to earning ratio (P/E)
15.77x
Price to sales ratio (P/S)
2.80x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
15.77x
Price to sales ratio (P/S)
2.80x
Valuation ratios
‪0.00‬
‪0.80‬
‪1.60‬
‪2.40‬
‪3.20‬
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪5.00‬
‪10.00‬
‪15.00‬
‪20.00‬
P/E
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪10%‬
‪13%‬
‪16%‬
‪19%‬
‪22%‬
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪‪900.00 M‬‬
‪‪1.80 B‬‬
‪‪2.70 B‬‬
‪‪3.60 B‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪0.00‬
‪‪800.00 M‬‬
‪‪1.60 B‬‬
‪‪2.40 B‬‬
‪‪3.20 B‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪0.00‬
‪‪800.00 M‬‬
‪‪1.60 B‬‬
‪‪2.40 B‬‬
‪‪3.20 B‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
Chemical Drug Preparations
Active Pharmaceutical Ingredients and Intermediates
Traditional Chinese Medicine Preparations
Diagnostic Reagents and Equipment
Biological Products
Other Activities
Sales Materials, Processing Charge, Etc.
Other
Lease
By country
Period: 2024
China
Overseas

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
Q2 '24
Q3 '24
Q4 '24
Q1 '25
Q2 '25
‪0.00‬
‪‪900.00 M‬‬
‪‪1.80 B‬‬
‪‪2.70 B‬‬
‪‪3.60 B‬‬
Actual
Estimate
Earnings
Next:Aug 21, 2025
Q2 '24
Q3 '24
Q4 '24
Q1 '25
Q2 '25
‪0.00‬
‪0.20‬
‪0.40‬
‪0.60‬
‪0.80‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

Dividend summary
48.17%
Earnings retained
Payout ratio (TTM)
Dividend yield TTM
3.71%
Last payment
1.35
Last ex-date
Jul 8, 2024
Last pay date
Jul 8, 2024
Dividend history
‪2.5%‬
‪3.1%‬
‪3.7%‬
‪4.3%‬
‪4.9%‬
2020
2021
2022
2023
2024
‪0.00‬
‪0.40‬
‪0.80‬
‪1.20‬
‪1.60‬
Dividends per share (FY)
Dividend yield (FY) %

Financial health

Financial position and solvency of the company

Debt level and coverage
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪‪3.00 B‬‬
‪‪6.00 B‬‬
‪‪9.00 B‬‬
‪‪12.00 B‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪4.50 B‬‬
‪‪9.00 B‬‬
‪‪13.50 B‬‬
‪‪18.00 B‬‬
Assets
Liabilities